Proteoglycans as a Critical Facet of a Healthy Extracellular Matrix
Salmon Nasal Cartilage–Derived Proteoglycans Offer Anti-Aging Benefits to Joints and Skin By Dr Carrie Decker ND
We often don’t know what we have until it is gone. Our youthful skin with its healthy glow, the ease with which we jump out of bed to take a morning run: these are things we often do not recognise as important until they start to change.
With osteoarthritis (OA) affecting more than 15% of the population over the age of 30, and leading to the prescription of nonsteroidal anti-inflammatory drugs (NSAIDs) in over 50% of those affected, and opioids in approximately one-third, we can’t deny the impact of this chronic degenerative condition. The medical costs associated with osteoarthritis are also significant: a 2009 survey showed this condition cost insurance companies in the USA over $4,000 per affected person yearly and also contributed to out-of-pocket costs of roughly $1,000 a year. The numbers don’t improve with age: more than 5% of individuals have had a total hip replacement, and 10% a total knee replacement, by age 80.
Although cosmetic skin procedures don’t fall in the realm of necessary medical care, they are still often sought out: over 15.9 million surgical and minimally invasive cosmetic procedures were performed in the U.S. in 2015, a 2% increase from 2014. The skin care industry is booming, with advertisements for skin care supplements, products, and devices pervasive in print, television, and online media. Collagen, once something we only found in homemade bone broths and soups, can now be found in virtually every format, from natural sodas to hand-warming beverages.
Although collagen as a supplement has considerable evidence for its support of the skin and joints, proteoglycans are also critical to the health of the extracellular matrix and are fast receiving interest given the array of clinical studies showing their benefits.
Proteoglycans: Critical for the Health and Integrity of the Extracellular Matrix
Articular cartilage, which covers the ends of the long bones where they come together to form joints, contains high amounts of type II collagen and proteoglycans made by the chondrocytes found within it. Type II collagen is the primary structural backbone of the matrix, with many molecules of aggrecan, a large proteoglycan that contains covalently bound chondroitin sulfate and keratan sulfate chains (collectively known as glycosaminoglycans [GAGs]), interacting with the collagen fibril network and hyaluronic acid through proteins known as link proteins.,, More than 65% of articular cartilage by weight is fluid, largely retained in the cartilage by the hydrophilic nature of the proteoglycans and hyaluronic acid, with only 5% of the cartilage volume being occupied by chondrocytes. Unfortunately, chondrocytes have minimal ability to replicate, and their ability to synthesise cartilage and proteoglycans declines with age, which is one issue that contributes to diminished articular tissue integrity with age.
Proteoglycans are also essential to the health of the skin. Similar to cartilage, proteoglycans affect the skin’s functional properties and structural integrity, in part by retaining moisture in the tissue. With aging and sun exposure, the composition of proteoglycans in the skin dramatically shifts, contributing to different tissue properties, diminished hydration, loss of skin viscoelasticity, and altered wound healing.,,
Cartilage Degeneration in Osteoarthritis and the Impact of Proteoglycans
In addition to chondrocyte senescence, other factors also contribute to the histological changes and eventual degeneration of articular tissue, and the associated symptoms of joint stiffness, pain, and loss of mobility typical of OA. Two phases of OA have been described: a biosynthetic phase, in which the chondrocytes are actively involved in tissue repair, and a degenerative phase that follows, in which matrix synthesis is inhibited and the chondrocytes themselves contribute to the production of enzymes involved in cartilage degradation. Focal lesions from which these changes initiate have also been implicated in the pathogenesis of OA, with increased mechanical forces due to joint instability contributing to cartilage degradation.
In addition to holding moisture in the tissue matrix, proteoglycans help structurally protect the cartilage from deterioration. As OA progresses, however, the proteoglycans are lost from the superficial articular cartilage surface to which the type II collagen runs parallel and the highest tensile forces, due to shear stress, exist. As the body dynamically attempts to remodel and repair the tissue in the early stages of OA, an increase in proteoglycans is seen deeper within the tissue, as if the body is attempting to counteract the surface changes. The concentration of proteoglycans decreases in the later stages of disease, however, with proteoglycan fragments in addition to the enzymes contributing to their degradation being observed in the joint synovial fluid., The degradation of aggrecans via a family of enzymes collectively known as aggrecanases has been recognized as a major mechanism contributing to the histopathological changes associated with OA, and medications directed at inhibiting this process are in an ongoing process of investigation.
OA is often accompanied by systemic inflammatory changes, with human studies showing higher levels of high-sensitivity C-reactive protein (hs-CRP) in populations who experience this condition. These changes are seen early in the disease, even after adjustment for age, weight, lifestyle factors, and injury., High levels of hs-CRP predict disease progression and are related to disease severity, and correlated with local tissue changes and inflammatory infiltrates in the synovial membranes and fluid of the involved joint., With the inflammation typical of OA as well as rheumatoid arthritis (RA), levels of prostaglandin E2 (PGE2), interleukin (IL)-1, and tumor necrosis factor alpha (TNF-α) also increase and contribute to proteoglycan and cartilage degradation.,,,
Interestingly, protein fragments (known as link proteins) of proteoglycan aggregates found in cartilage have been observed to stimulate proteoglycan and collagen synthesis in in vitro studies., The link protein N-terminal peptide has also been shown to stimulate cartilage regeneration by increasing the proliferation, migration, and chondrogenic differentiation of cartilage stem/progenitor cells. Additionally, link protein N-terminal peptide counteracts degenerative changes induced by IL-1α.
The Dynamic Array of Research Behind Salmon Cartilage–Derived Proteoglycans
Salmon nasal cartilage is one source of proteoglycans that has been highly researched with positive findings in a myriad of settings, including several animal models of autoimmunity,,,, allergies, infection, wound healing, diet-induced inflammation, and ultraviolet (UV) light–associated skin damage, as well as clinical studies of joint pain, arthritis, and skin aging.
Salmon nasal cartilage primarily contains the proteoglycan aggrecan, which has an amino acid composition and functional domains very similar to the aggrecan found in the articular cartilage of mammals. In cell cultures, salmon nasal cartilage proteoglycans (SNCPs) have been shown to reduce matrix metalloproteinase expression, a primary contributor to cartilage degradation. Early studies performed with SNCPs in macrophages stimulated with heat-killed Escherichia coli suggest these proteoglycans have immunomodulatory and anti-inflammatory effects—treatment with the SNCP solution reduced levels of the pro-inflammatory cytokine TNF-α and nitric oxide synthase (also a contributor to the joint destruction in OA), and increased IL-10.
Clinical Studies with SNCPs.
There is strong clinical data supporting the use of SNCPs for the management of joint pain and as an anti-aging skin strategy. Very low oral doses of proteoglycans, ranging from 5 to 10 mg daily, have evidence in these regards.
In healthy subjects (40 to 75 years of age) complaining of some level of discomfort in the knee joint, 5 mg of SNCPs taken daily led to significant improvements in the Visual Analogue Scale (VAS) comprehensive scores in the proteoglycan group compared to placebo after four weeks, paralleled by a trend of reduction in hs-CRP levels.47 In a similar study, healthy subjects with knee discomfort taking 10 mg of SNCPs daily for 12 weeks were found to have significantly improved aggregate Japanese Knee Injury and Osteoarthritis Outcome Score (J-KOOS) scores compared to placebo at weeks four and twelve, and there were also significant intragroup improvements in knee range of motion and pain VAS scores associated with both movement and rest. Analysis of markers of collagen breakdown and synthesis showed significantly reduced collagen degradation and a nonsignificant increase in collagen synthesis in aging individuals with knee joint discomfort taking 10 mg of SNCPs daily for 16 weeks compared to placebo.[56
A combination of type II collagen and SNCPs has also been clinically studied and shown to improve joint discomfort and function at low doses. In healthy subjects experiencing rigidity of the knee, daily supplementation with 50 mg of salmon nasal cartilage, containing 40% undenatured type II collagen and 30% proteoglycans, significantly improved Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and pain VAS scores by four weeks, compared to placebo.48
Skin appearance and tissue quality have also been shown to improve with a low daily dose of proteoglycans. Men and women (with a mean age of 39 to 40 years) who took 5 mg of SNCPs daily for only two weeks were found to have significantly increased skin viscoelasticity and recovery after deformation, and decreased skin looseness, compared to placebo.49 Additionally, there was a significantly decreased appearance of wrinkles, conspicuous facial pores, and blotches within the SNCP group. Improved skin conductance, signifying improved hydration, and reduced roughness as evaluated by skin micrographs, were also seen in those taking SNCPs. Given that the time for turnover of the cells in the skin is normally more than 28 days, it is possible that these effects may have been even more significant or dramatic after a longer period of time.
As these studies suggest, the health benefits SNCPs may confer extend beyond their importance as a structural element of the extracellular matrix. As we continue to learn more about the signaling that occurs between the extracellular matrix and the immune system, and the role the extracellular matrix plays in other facets of health and disease, it is likely we will further understand the mechanisms via which proteoglycans may have such a dramatic impact on health.
 Birtwhistle R, et al. Prevalence and management of osteoarthritis in primary care: an epidemiologic cohort study from the Canadian Primary Care Sentinel Surveillance Network. CMAJ Open. 2015 Jul 17;3(3):E270-5.
 Kotlarz H, et al. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. 2009 Dec;60(12):3546-53.
 Maradit Kremers H, et al. Prevalence of Total Hip and Knee Replacement in the United States. J Bone Joint Surg Am. 2015 Sep 2;97(17):1386-97.
 American Society of Plastic Surgeons. New statistics reflect the changing face of plastic surgery [Internet]. Arlington Heights (IL): American Society of Plastic Surgeons; 2016 [cited 2018 Nov 5]. Available from: https://www.plasticsurgery.org/news/press-releases/new-statistics-reflect-the-changing-face-of-plastic-surgery
 Figueres Juher T, Basés Pérez E. [An overview of the beneficial effects of hydrolyzed collagen intake on joint and bone health and on skin aging]. Nutr Hosp. 2015 Jul 18;32 Suppl 1:62-6.
 Poole AR, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii78-81.
 Hardingham TE. The role of link-protein in the structure of cartilage proteoglycan aggregates. Biochem J. 1979 Jan 1;177(1):237-47.
 Kiani C, et al. Structure and function of aggrecan. Cell Res. 2002 Mar;12(1):19-32.
 Mow VC, et al. Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures. Biomaterials. 1992;13:67-97
 Roughley PJ, Lee ER. Cartilage proteoglycans: structure and potential functions. Microsc Res Tech. 1994 Aug 1;28(5):385-97.
 Hou A, et al. Cellular senescence in osteoarthritis and anti-aging strategies. Mech Ageing Dev. 2018 Aug 11. pii: S0047-6374(18)30062-9.
 Smith MM, Melrose J. Proteoglycans in Normal and Healing Skin. Adv Wound Care (New Rochelle). 2015 Mar 1;4(3):152-73.
 Carrino DA, et al. Age-related changes in the proteoglycans of human skin. Arch Biochem Biophys. 2000 Jan 1;373(1):91-101.
 Röck K, Fischer JW. [Role of the extracellular matrix in extrinsic skin aging]. Hautarzt. 2011 Aug;62(8):591-7.
 Maquart FX. Extracellular matrix: a major partner of wound healing. Bull Acad Natl Med. 2015 Oct;199(7):1199-209.
 Sandell LJ, et al. Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis. Arthritis Res. 2001;3(2):107-13.
 Heijink A, et al. Biomechanical considerations in the pathogenesis of osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc. 2012 Mar;20(3):423-35.
 Poole AR, et al. Osteoarthritis in the human knee: a dynamic process of cartilage matrix degradation, synthesis and reorganization. Agents Actions Suppl. 1993;39:3-13.
 Rizkalla G, et al. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest. 1992 Dec;90(6):2268-77.
 Lohmander LS, et al. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993 Feb;36(2):181-9.
 Lohmander LS, et al. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993 Sep;36(9):1214-22.
 El Bakali J, et al. Inhibition of aggrecanases as a therapeutic strategy in osteoarthritis. Future Med Chem. 2014;6(12):1399-412.
 Spector TD, et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum. 1997 Apr;40(4):723-7.
 Sharif M, et al. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis. 2000 Jan;59(1):71-4.
 Wolfe F. The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol. 1997 Aug;24(8):1486-8.
 Stürmer T, et al. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein. Ann Rheum Dis. 2004 Feb;63(2):200-5.
 Pearle AD, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage. 2007 May;15(5):516-23.
 Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011 Sep;23(5):471-8.
 Hardy MM, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum. 2002 Jul;46(7):1789-803.
 Gosset M, et al. Mechanical stress and prostaglandin E2 synthesis in cartilage. Biorheology. 2008;45(3-4):301-20.
 Xue J, et al. Tumor necrosis factor-α induces ADAMTS-4 expression in human osteoarthritis chondrocytes. Mol Med Rep. 2013 Dec;8(6):1755-60.
 Yang B, et al. Effect of microRNA-145 on IL-1β-induced cartilage degradation in human chondrocytes. FEBS Lett. 2014 Jun 27;588(14):2344-52.
 Buckwalter JA, et al. Electron microscopic studies of cartilage proteoglycans. Electron Microsc Rev. 1988;1(1):87-112.
 Liu H, et al. An N-terminal peptide from link protein can stimulate biosynthesis of collagen by human articular cartilage. Arch Biochem Biophys. 2000 Jun 1;378(1):116-22.
 McKenna LA, et al. An N-terminal peptide from link protein stimulates proteoglycan biosynthesis in human articular cartilage in vitro. Arthritis Rheum. 1998 Jan;41(1):157-62.
 He R, et al. Link protein N-terminal peptide as a potential stimulating factor for stem cell-based cartilage regeneration. Stem Cells Int. 2018 Jan 30;2018:3217895.
 Yeh CH, et al. Link protein N-terminal peptide and fullerol promote matrix production and decrease degradation enzymes in rabbit annulus cells. Connect Tissue Res. 2018 Mar;59(2):191-200.
 Majima M, et al. Effect of proteoglycan on experimental colitis. International Congress Series. 2001 Dec 1;1223:221-4.
 Mitsui T, et al. Salmon cartilage proteoglycan suppresses mouse experimental colitis through induction of Foxp3+ regulatory T cells. Biochem Biophys Res Commun. 2010 Nov 12;402(2):209-15.
 Sashinami H, et al. Salmon proteoglycan suppresses progression of mouse experimental autoimmune encephalomyelitis via regulation of Th17 and Foxp3(+) regulatory T cells. Life Sci. 2012 Dec 17;91(25-26):1263-9.
 Yoshimura S, et al. Attenuation of collagen-induced arthritis in mice by salmon proteoglycan. Biomed Res Int. 2014;2014:406453.
 Ono HK, et al. Salmon cartilage proteoglycan attenuates allergic responses in mouse model of papain induced respiratory inflammation. Mol Med Rep. 2018 Oct;18(4):4058-64.
 Hirose S, et al. Salmon cartilage proteoglycan promotes the healing process of Staphylococcus aureus-infected wound. Heliyon. 2018 Mar 27;4(3):e00587.
 Asano K, et al. Oral administration of salmon cartilage proteoglycan extends the survival of allografts in mice. Biomed Rep. 2018 Jan;8(1):37-40.
 Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008;14(12):1225-30.
 Goto M, et al. Anti-aging effects of high molecular weight proteoglycan from salmon nasal cartilage in hairless mice. Int J Mol Med. 2012 May;29(5):761-8.
 Kuriyama Y, Yoshida Y. Efficacy of dietary supplement contained proteoglycan extracted from salmon nasal cartilage on knee uncomfortableness in healthy volunteers. Jpn Pharmacol Ther. 2017;45:1795-808.
 Kuriyama Y, et al. Effects of taking salmon nasal cartilage extract (containing undenatured type II collagen and undenatured proteoglycan) on knee joint pain. J New Rem & Clin. 2016;65(11).
 Takahashi T, et al. Ingestion of salmon nasal cartilage-derived proteoglycan improves skin condition: A randomized, double-blind, controlled study. Immun Endoc Metab Agents Med Chem. 2015 Aug 1;15(2):160-7.
 Kakizaki I, et al. Identification of proteoglycan from salmon nasal cartilage. Arch Biochem Biophys. 2011 Feb 1;506(1):58-65.
 Kobayashi T, et al. Chondroitin sulfate proteoglycans from salmon nasal cartilage inhibit angiogenesis. Biochem Biophys Rep. 2016 Nov 18;9:72-8.
 Tetlow LC, et al. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001 Mar;44(3):585-94.
 Sashinami H, et al. Salmon cartilage proteoglycan modulates cytokine responses to Escherichia coli in mouse macrophages. Biochem Biophys Res Commun. 2006 Dec 29;351(4):1005-10.
 Pelletier JP, et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum. 2000 Jun;43(6):1290-9.
 Najima M, et al. Usefulness of the supplement containing proteoglycan for Japanese healthy people feeling knee’s discomfort. Shinryo to Shinyaku (Med Cons New-Remed). 2016;53(3):228-36.
 Tomonaga A, et al. Evaluation of the effect of salmon nasal proteoglycan on biomarkers for cartilage metabolism in individuals with knee joint discomfort: A randomized double-blind placebo-controlled clinical study. Exp Ther Med. 2017 Jul;14(1):115-26.
 Weinstein GD, et al. Cell proliferation in normal epidermis. J Invest Dermatol. 1984 Jun;82(6):623-8.
 Kim SH, et al. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011 May;209(2):139-51.
 Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol. 2000 Feb;67(2):149-59.
 Bonnans C, et al. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801.
9 Responses to “Proteoglycans as a Critical Facet of a Healthy Extracellular Matrix”
Leave a Reply
- Reading Time: 2 minutes #Parkinson’s disease i...
- Reading Time: 2 minutes In recent years, the #...
- Reading Time: 3 minutes Dear practitioner Vita...
- Reading Time: 2 minutes The #COVID-19 pandemic...
- Reading Time: < 1 minute The popularity of ...
Updates on your email
Don't miss out on our email updates